Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03401216
Other study ID # Exeption
Secondary ID
Status Recruiting
Phase N/A
First received December 25, 2017
Last updated January 15, 2018
Start date March 20, 2017
Est. completion date April 30, 2019

Study information

Verified date January 2018
Source Meshalkin Research Institute of Pathology of Circulation
Contact Aleksei Prokhorikhin, MD
Phone +79137178040
Email turbogold@list.ru
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to evaluate the rate of SYNERGY 48 mm stent strut coverage and assess neointimal progression via OCT measurement in patients who underwent PCI.


Description:

Patients with stable, unstable angina and non-ST-elevation ACS will be included in this study. Patient will undergo coronary angiography for coronary anatomy assessment and estimation indications for PCI . After screening an OCT-guided PCI with extra long SYNERGY stent implantation will be provided in all patients. Patient will be divided into 2 groups of follow-up and will be followed within 3 and 6 month after procedure. Final clinical follow-up will be assessed at 12 month for all patients. At each follow-up visits the data regarding clinical events, coronary angiography and OCT-imaging will be collected.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date April 30, 2019
Est. primary completion date April 30, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Signed written informed consent before study procedures

- Subject is eligible for percutaneous coronary intervention (PCI)

- Left ventricular ejection fraction (LVEF) >30%

- Reference vessel diameter (RVD) =2.25 mm and =4.0 mm

- Target lesion(s) length must be =38 mm

- Target lesion(s) stenosis =50%

Exclusion Criteria:

- History of acute or recent stroke (<2 months)

- Contraindications for antiplatelet and/or anticoagulant therapy

- Bleeding within the last 30 days

- Subject has acute ST elevation MI (STEMI)

- Subject has cardiogenic shock, hemodynamic instability requiring inotropic or mechanical circulatory support

- Subject with out of range complete blood count (CBC) values determined as a clinically significant

- Subject has documented or suspected liver disease, including laboratory evidence of hepatitis

- Subject has baseline serum creatinine level >2.0 mg/dL (177µmol/L)

- Subject has signs or symptoms of active heart failure (i.e., NYHA class IV) at the time of the index procedure

- Subject is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential)

- Lesion located within a saphenous vein graft or an arterial graft

- Subject has unprotected left main coronary artery disease (>50% diameter stenosis)

- Other serious medical illness (e.g., cancer, congestive heart failure) that may reduce life expectancy to less than 12 months

Study Design


Intervention

Device:
SYNERGY 48 mm
Material: Platinum-Chromium alloy. Stent strut thickness: 0.0029-0.0032 inches. Polymer carrier composed of PLGA (poly(DL-lactide-co-glycolide)). Drug product: Everolimus, 1µg per 1 mm2. Stent diameters available: 2.25; 2.50; 2.75; 3.00; 3.50; 4.00 mm. Stent length: 48 mm. Nominal balloon pressure: 11 atm. (1117 kPa). Manufacturing company: Boston Scientific Corporation (USA)
Procedure:
PCI
Standard PCI procedure
3 month OCT follow-up
Optical coherence tomography imaging of target vessel within 3 month after PCI
6 month OCT follow-up
Optical coherence tomography imaging of target vessel within 5 month after PCI

Locations

Country Name City State
Russian Federation Academician E.N. Meshalkin national medical research center Novosibirsk

Sponsors (2)

Lead Sponsor Collaborator
Meshalkin Research Institute of Pathology of Circulation Boston Scientific Corporation

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Other Target lesion failure (TLF) TLF is defined as a composite endpoint of cardiac death, target vessel myocardial infarction and clinically indicated target lesion revascularization. 12 month after PCI
Other Cardiac death Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. 12 month after PCI
Other Myocardial infarction Type 1, 2, 3, 4a, 4b according to Third Universal Definition of Myocardial Infarction 12 month after PCI
Other Stent thrombosis Definite and probable, according to ARC definition, 12 month after PCI
Primary Neointimal healing score The neointimal healing score is based on four stent-related characteristics and is calculated on a lesion level:
Presence of filling defect (% intraluminal defect, ILD) is assigned a weight of "4".
Presence of both malapposed and uncovered struts (% malapposed/ uncovered, MU) is assigned a weight of "3"
Presence of uncovered struts alone (% malapposed, M) is assigned a weight of "2"
Presence of malapposed struts alone (% uncovered, U) is assigned a weight of "1"
within 3 month after PCI
Primary Neointimal healing score The neointimal healing score is based on four stent-related characteristics and is calculated on a lesion level:
Presence of filling defect (% intraluminal defect, ILD) is assigned a weight of "4".
Presence of both malapposed and uncovered struts (% malapposed/ uncovered, MU) is assigned a weight of "3"
Presence of uncovered struts alone (% malapposed, M) is assigned a weight of "2"
Presence of malapposed struts alone (% uncovered, U) is assigned a weight of "1"
within 6 month after PCI
Secondary Percentage of strut coverage assessed by OCT In metallic DES, the struts are classified as covered in the presence of a coverage thickness >0 µm (tissue can be identified above the struts). within 3 month after PCI
Secondary Percentage of strut coverage assessed by OCT In metallic DES, the struts are classified as covered in the presence of a coverage thickness >0 µm (tissue can be identified above the struts). within 6 month after PCI
Secondary Percentage of mature neointimal tissue assessed by OCT To assess mature neointima an OCT-based grey-scale-signal-intensity (GSI)-analysis will be performed. within 3 month after PCI
Secondary Percentage of mature neointimal tissue assessed by OCT To assess mature neointima an OCT-based grey-scale-signal-intensity (GSI)-analysis will be performed. within 6 month after PCI
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A